Global Bispecific Antibody Drug Conjugates Bispecific ADC Clinical Trials Commercial ...
Bispecific antibody drug conjugates (BsADCs) represent a cutting-edge advancement in cancer therapy, addressing tumor resistance and heterogeneity with dual-targeting mechanisms. Over 60 BsADCs are currently in clinical trials, offering targeted, multi-faceted treatment with reduced side effects. Recent technological advancements have enabled efficient production, expanding their potential applications beyond cancer to autoimmune and infectious diseases.
Reference News
Bispecific antibody drug conjugates (BsADCs) represent a cutting-edge advancement in cancer therapy, addressing tumor resistance and heterogeneity with dual-targeting mechanisms. Over 60 BsADCs are currently in clinical trials, offering targeted, multi-faceted treatment with reduced side effects. Recent technological advancements have enabled efficient production, expanding their potential applications beyond cancer to autoimmune and infectious diseases.
First bispecific antibody drug conjugate expected in market by 2029; China leads in clinical trials; major focus on breast cancer; key companies involved; collaborations and licensing agreements accelerate development; regulatory approvals increasing; patent landscape complex; market growth anticipated with late-stage clinical trial results.
Bispecific antibody drug conjugates (BsADCs) market poised for growth, with China leading in clinical trials and first commercial approval expected by 2029. Key players include Alhamab Oncology and Sichuan Baili Pharmaceutical, with BsADCs targeting breast cancer and solid tumors. Regulatory agencies are increasingly approving BsADC candidates for clinical trials, and collaborations are accelerating development.